Most linked-to pages
From Glioblastoma Treatments
Jump to navigationJump to search
Showing below up to 8 results in range #201 to #208.
- Phase 3 (2 links)
- Preclinical studies (2 links)
- 13.5 months for general cases, 19.5 months for patients with MGMT methylated tumors. (2 links)
- 17 months for general cases, 25.5 months for patients with MGMT methylated tumors when administered in the morning. (2 links)
- Improved in morning dosing, exact data still under investigation. (2 links)
- Standard progression statistics for GBM. (2 links)
- Category:Investigational Drugs (2 links)
- 4.5 (2 links)